New investors, the most recent short interest is < 1% of

New Post Public Reply Private Reply Replies (0) Message Board
Phteven C
218
New investors, the most recent short interest is < 1% of the OS and the most recent failure-to-deliver (naked short) # is a measly 6640 shares. IMHO interpreting short volume as actual short sales is misleading. This is what FINRA, the exact same source which the #s are posted from, said.

"Thank you for contacting FINRA’s Office of the Ombudsman. Regarding your question, it would be incorrect to assume that short sales comprise 32% of the total volume on that trading day for IPIX . FINRA publishes the daily short sale volume pursuant to an SEC mandate; however, there are various trading anomalies that result in the reported short sale volume often being exaggerated. Thus, the true total short sales volume may be significantly lower than the volume that is reported. Third parties sometimes ignore this and try to claim the ratio is valid to further their own objectives. "

https://investorshangout.com/post/view?id=4804282

You can also check out these two posts for some detailed explanations.

https://investorshangout.com/post/view?id=4670279

https://investorshangout.com/post/view?id=4816479

Here are the official short interest and failure-to-deliver data.

Settlement Date: 10/31/2017
Current Short: 1,274,605
Previous Short: 1,227,218
Change: 47,386 (3.86%)
Average Daily Volume: 361,557
Days to Cover: 3.53

0.91% of the outstanding shares were short.

http://otce.finra.org/ESI

According to the SEC, only 6,640 shares (0.005% of the OS) were failure-to-deliver as of September 29.

20170929|45782D100|IPIX|6640|INNOVATION PHARMACEU|0.71

https://www.sec.gov/data/foiadocsfailsdatahtm

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Arclin's Bold Bet: Expanding Nomex Capacity in Spain

Updated Category News Views 5

Arclin's Strategic Move for Nomex® Expansion Looks like Arclin’s not messing around. They're throwing some serious cash down in Asturias, Spain, to ramp up production of Nomex®—a material hotter than a blacktop in July with demand surging across aerospace, electric vehicles, and defense sectors. "When we bought the Nomex® business, we committed to investing in its...

Continue Reading
Unicycive Faces Stock Plunge and Legal Woes After FDA Setback

Updated Category News Views 5

Unicycive's Rough Ride: Not Just a Bump Picture this: Your stock takes a nosedive over 39% in a day, just after a critical drug application gets slammed by the FDA—for the second time. That’s the story with Unicycive Therapeutics, Inc., ticker NASDAQ: UNC, a company that's been handing out one nail-biting moment after another to its investors. It's not just a minor...

Continue Reading
ELEGOO's M1 Ultra: Bridging Gap in 3D Scanning Tech

Updated Category News Views 0

A Leap in 3D Scanning: Say Hello to M1 Ultra ELEGOO isn't just fiddling with a toy here—this Shenzhen-based juggernaut is rolling out the M1 Ultra on October 29, 2026, and it's causing quite a stir. While the stock market doesn't see immediate tremors from every shiny new gadget, there’s something to say when a company that pulled over $300 million in sales last year...

Continue Reading
Side Bolsters Art Division with Roboto Acquisition

Updated Category News Views 7

Breaking Into China's Game Art Market The gaming industry's latest buzz centers around Side's acquisition of Roboto Entertainment, a boutique art studio known for crafting immersive game environments. This isn't just another headline grab—this move puts Side smack dab in the heart of China's burgeoning game market with a fresh Chengdu base. Expansion With Strategic...

Continue Reading
S&T Bancorp Hits Record Highs in Q3 2026

Updated Category News Views 3

Surpassing Expectations with Record Metrics Well, if it isn’t another stellar quarter for S&T Bancorp (NASDAQ:STBA). The folks over in Indiana, PA, just threw down some serious numbers. The third quarter of 2026 saw net income climbing to $38.6 million, up from $36.6 million last quarter. That's a decent hike if you ask me. But what really stole the spotlight here was...

Continue Reading
Savarese Joins RID to Drive Diagnostic Innovation

Updated Category News Views 5

A Seasoned Leader Bolsters RID's Ambitions Mario Savarese has joined Rapid Infection Diagnostics Inc.'s Strategic Advisory Board, and let me tell ya, this move's got potential. Appointing a heavyweight like Savarese as an advisor isn’t just a nod to his hefty resume. It’s about vaulting a burgeoning company into the big leagues. He's got over 20 years steering a ship...

Continue Reading
Tairex's AI System Targets Global Healthcare Gaps

Updated Category News Views 6

AI Meets Human Expertise in Clinical Decision-Making Look, in the labyrinth of healthcare, we’re seeing a revolution with AI stepping in—not to replace the doctor, but to stand alongside them like a trusty assistant. Tairex, from the halls of Tsinghua University's Institute for AI Industry Research (AIR), has thrown its hat into this ring by unveiling their...

Continue Reading
Montega Kicks Off Agilyx Sponsored Equity Research

Updated Category News Views 1

A Fresh Take on Agilyx's Market Standing Alright, folks. Agilyx ASA just got a new ticket for the analytical rodeo as Montega AG dives into sponsored equity research on the company. For those who aren't fluent in the arcane dialect of stock enthusiasts like yours truly, this means Agilyx now has another sharp set of eyes evaluating their every move, and let me tell you,...

Continue Reading
Nel ASA Welcomes Morten Holum as New CEO by 2027

Updated Category News Views 7

Nel ASA's New Leader Announced In the latest shake-up at Nel ASA (OSE: NEL), Morten Holum is getting ready to take the reins as CEO. By May 1, 2027, Holum will step into the shoes left by Håkon Volldal. And folks, this isn't your average leadership swap. Holum brings a hefty toolkit to this hydrogen powerhouse, having been part of the action across the hydrogen value...

Continue Reading
Amcor's Q3 2026 Results Loom: What's at Stake?

Updated Category News Views 3

Anticipation Builds for Amcor's Q3 2026 Financials Well, here we are again, staring down the barrel of another quarterly earnings report from Amcor plc (NYSE: AMCR). They've circled November 4th, 2026, in red on their calendars to dish out the numbers after the U.S. market's last bell rings. Investors, analysts, and the peanut gallery will be tuning in, and why not? At a...

Continue Reading

Top 5 Most Recently Viewed Articles

Freeport-McMoRan Legal Update: Key Actions for Investors

Updated Category News Views 256

Understanding the Importance of Class Actions for Investors In the world of investing, class actions serve as crucial tools for holding companies accountable for their actions. Investors, particularly those who have purchased stocks during a defined time frame, like those involved with Freeport-McMoRan Inc. (NYSE: FCX), stand to benefit significantly from these legal...

Continue Reading
Investigation into ADMA Biologics Growth Potential and Risks

Updated Category News Views 58

Insights into ADMA Biologics and Ongoing Investigations Investors interested in ADMA Biologics, Inc. should be aware that the company is currently under investigation for potential securities fraud, prompting discussions about recovery options for those impacted. Understanding these developments can offer investors crucial insights into the company's future prospects and...

Continue Reading
Kuehn Law Assists Zentalis Pharmaceuticals Investors in Rights Endeavors

Updated Category News Views 82

Understanding Your Rights as a Zentalis Investor Kuehn Law, a prominent shareholder litigation firm, is currently investigating the actions of the management team at Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL). The focus lies on whether certain officers and directors have acted in ways that undermine their fiduciary responsibilities. These responsibilities include...

Continue Reading
Navigating Market Challenges: Insights into Recent Trends

Updated Category News Views 180

Understanding Current Market Dynamics In a time of significant market fluctuations, risk assets are facing pressure due to a complex mix of economic indicators and investor sentiment. Recent developments in US equities have created a landscape where volatility is the norm. This analysis will delve into various market segments, focusing on key events that shape the current...

Continue Reading
Harnessing Waste Heat: The Future of Clean Energy Deployment

Updated Category News Views 102

Harnessing Waste Heat to Drive Clean Energy Solutions ATS Energy, a trailblazer in renewable energy technology, is making significant strides in turning industrial waste heat into valuable electricity. This revolutionary process not only enhances energy efficiency but also contributes to a more sustainable future. The introduction of the bipartisan Waste Heat to Wattage...

Continue Reading